Does the media favor BDX or GMED?

In the previous week, Becton, Dickinson and Company had 15 more articles in the media than Globus Medical. MarketBeat recorded 24 mentions for Becton, Dickinson and Company and 9 mentions for Globus Medical. Becton, Dickinson and Company's average media sentiment score of 1.19 beat Globus Medical's score of 1.03 indicating that Becton, Dickinson and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Becton, Dickinson and Company 18 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Globus Medical 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, GMED or DXCM?

DexCom has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Globus Medical $2.94B 3.65 $537.87M $4.30 18.40 DexCom $4.66B 6.00 $836.30M $2.34 30.97

Is GMED or DXCM more profitable?

DexCom has a net margin of 19.31% compared to Globus Medical's net margin of 18.92%. DexCom's return on equity of 33.33% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets Globus Medical 18.92% 13.46% 11.65% DexCom 19.31% 33.33% 13.19%

Does the media refer more to GMED or DXCM?

In the previous week, DexCom had 13 more articles in the media than Globus Medical. MarketBeat recorded 22 mentions for DexCom and 9 mentions for Globus Medical. DexCom's average media sentiment score of 1.17 beat Globus Medical's score of 1.03 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 17 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, GMED or RMD?

ResMed has higher revenue and earnings than Globus Medical. ResMed is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Globus Medical $2.94B 3.65 $537.87M $4.30 18.40 ResMed $5.15B 5.32 $1.40B $10.37 18.21

Is GMED or RMD more profitable?

ResMed has a net margin of 27.44% compared to Globus Medical's net margin of 18.92%. ResMed's return on equity of 25.35% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets Globus Medical 18.92% 13.46% 11.65% ResMed 27.44% 25.35% 18.69%

Does the media refer more to GMED or RMD?

In the previous week, ResMed had 6 more articles in the media than Globus Medical. MarketBeat recorded 15 mentions for ResMed and 9 mentions for Globus Medical. Globus Medical's average media sentiment score of 1.03 beat ResMed's score of 0.83 indicating that Globus Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 6 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, GMED or STE?

STERIS has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Globus Medical $2.94B 3.65 $537.87M $4.30 18.40 STERIS $5.94B 3.33 $782.30M $7.93 25.55

Is GMED or STE more profitable?

Globus Medical has a net margin of 18.92% compared to STERIS's net margin of 13.18%. STERIS's return on equity of 14.15% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets Globus Medical 18.92% 13.46% 11.65% STERIS 13.18% 14.15% 9.52%

Does the media refer more to GMED or STE?

In the previous week, STERIS had 3 more articles in the media than Globus Medical. MarketBeat recorded 12 mentions for STERIS and 9 mentions for Globus Medical. STERIS's average media sentiment score of 1.14 beat Globus Medical's score of 1.03 indicating that STERIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive STERIS 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BAX or GMED?

In the previous week, Globus Medical had 4 more articles in the media than Baxter International. MarketBeat recorded 9 mentions for Globus Medical and 5 mentions for Baxter International. Globus Medical's average media sentiment score of 1.03 beat Baxter International's score of 0.54 indicating that Globus Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Baxter International 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Globus Medical 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Globus Medical (GMED) Competitors

$79.12 +3.70 (+4.91%)

Closing price 06/18/2026 03:59 PM Eastern

Extended Trading

$79.11 -0.01 (-0.01%)

As of 06/18/2026 07:53 PM Eastern

Compare

GMED vs. BDX, DXCM, RMD, STE, and BAX

Should you buy Globus Medical stock or one of its competitors? MarketBeat compares Globus Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Globus Medical include Becton, Dickinson and Company (BDX), DexCom (DXCM), ResMed (RMD), STERIS (STE), and Baxter International (BAX). These companies are all part of the "health care equipment" industry.

How does Globus Medical compare to Becton, Dickinson and Company?

Becton, Dickinson and Company (NYSE:BDX) and Globus Medical (NYSE:GMED) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

In the previous week, Becton, Dickinson and Company had 15 more articles in the media than Globus Medical. MarketBeat recorded 24 mentions for Becton, Dickinson and Company and 9 mentions for Globus Medical. Becton, Dickinson and Company's average media sentiment score of 1.19 beat Globus Medical's score of 1.03 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Becton, Dickinson and Company	18 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Globus Medical	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Becton, Dickinson and Company has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and Company	$21.84B	1.82	$1.68B	$3.95	36.45
Globus Medical	$2.94B	3.65	$537.87M	$4.30	18.40

Becton, Dickinson and Company presently has a consensus target price of $181.00, suggesting a potential upside of 25.71%. Globus Medical has a consensus target price of $105.00, suggesting a potential upside of 32.70%. Given Globus Medical's stronger consensus rating and higher probable upside, analysts plainly believe Globus Medical is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38
Globus Medical	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.87

Becton, Dickinson and Company has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Globus Medical has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Globus Medical has a net margin of 18.92% compared to Becton, Dickinson and Company's net margin of 5.33%. Becton, Dickinson and Company's return on equity of 15.37% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and Company	5.33%	15.37%	7.11%
Globus Medical	18.92%	13.46%	11.65%

87.0% of Becton, Dickinson and Company shares are owned by institutional investors. Comparatively, 95.2% of Globus Medical shares are owned by institutional investors. 0.4% of Becton, Dickinson and Company shares are owned by insiders. Comparatively, 18.4% of Globus Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Globus Medical beats Becton, Dickinson and Company on 11 of the 17 factors compared between the two stocks.

How does Globus Medical compare to DexCom?

Globus Medical (NYSE:GMED) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

DexCom has a net margin of 19.31% compared to Globus Medical's net margin of 18.92%. DexCom's return on equity of 33.33% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	18.92%	13.46%	11.65%
DexCom	19.31%	33.33%	13.19%

DexCom has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.65	$537.87M	$4.30	18.40
DexCom	$4.66B	6.00	$836.30M	$2.34	30.97

Globus Medical currently has a consensus price target of $105.00, suggesting a potential upside of 32.70%. DexCom has a consensus price target of $84.83, suggesting a potential upside of 17.06%. Given Globus Medical's higher probable upside, equities analysts clearly believe Globus Medical is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.87
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92

In the previous week, DexCom had 13 more articles in the media than Globus Medical. MarketBeat recorded 22 mentions for DexCom and 9 mentions for Globus Medical. DexCom's average media sentiment score of 1.17 beat Globus Medical's score of 1.03 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	17 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Globus Medical has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, DexCom has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

95.2% of Globus Medical shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 18.4% of Globus Medical shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

DexCom beats Globus Medical on 14 of the 17 factors compared between the two stocks.

How does Globus Medical compare to ResMed?

Globus Medical (NYSE:GMED) and ResMed (NYSE:RMD) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Globus Medical currently has a consensus target price of $105.00, suggesting a potential upside of 32.70%. ResMed has a consensus target price of $273.00, suggesting a potential upside of 44.57%. Given ResMed's higher probable upside, analysts clearly believe ResMed is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.87
ResMed	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 55.0% of ResMed shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by insiders. Comparatively, 0.7% of ResMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ResMed has a net margin of 27.44% compared to Globus Medical's net margin of 18.92%. ResMed's return on equity of 25.35% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	18.92%	13.46%	11.65%
ResMed	27.44%	25.35%	18.69%

In the previous week, ResMed had 6 more articles in the media than Globus Medical. MarketBeat recorded 15 mentions for ResMed and 9 mentions for Globus Medical. Globus Medical's average media sentiment score of 1.03 beat ResMed's score of 0.83 indicating that Globus Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	6 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ResMed has higher revenue and earnings than Globus Medical. ResMed is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.65	$537.87M	$4.30	18.40
ResMed	$5.15B	5.32	$1.40B	$10.37	18.21

Globus Medical has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, ResMed has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

Summary

ResMed beats Globus Medical on 9 of the 17 factors compared between the two stocks.

How does Globus Medical compare to STERIS?

Globus Medical (NYSE:GMED) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, STERIS had 3 more articles in the media than Globus Medical. MarketBeat recorded 12 mentions for STERIS and 9 mentions for Globus Medical. STERIS's average media sentiment score of 1.14 beat Globus Medical's score of 1.03 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Globus Medical has a net margin of 18.92% compared to STERIS's net margin of 13.18%. STERIS's return on equity of 14.15% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	18.92%	13.46%	11.65%
STERIS	13.18%	14.15%	9.52%

Globus Medical currently has a consensus target price of $105.00, suggesting a potential upside of 32.70%. STERIS has a consensus target price of $278.00, suggesting a potential upside of 37.22%. Given STERIS's higher probable upside, analysts clearly believe STERIS is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.87
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Globus Medical has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, STERIS has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

95.2% of Globus Medical shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 18.4% of Globus Medical shares are held by insiders. Comparatively, 1.1% of STERIS shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

STERIS has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.65	$537.87M	$4.30	18.40
STERIS	$5.94B	3.33	$782.30M	$7.93	25.55

Summary

Globus Medical beats STERIS on 9 of the 17 factors compared between the two stocks.

How does Globus Medical compare to Baxter International?

Baxter International (NYSE:BAX) and Globus Medical (NYSE:GMED) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Globus Medical had 4 more articles in the media than Baxter International. MarketBeat recorded 9 mentions for Globus Medical and 5 mentions for Baxter International. Globus Medical's average media sentiment score of 1.03 beat Baxter International's score of 0.54 indicating that Globus Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baxter International	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Globus Medical	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Baxter International currently has a consensus price target of $19.73, indicating a potential downside of 0.97%. Globus Medical has a consensus price target of $105.00, indicating a potential upside of 32.70%. Given Globus Medical's stronger consensus rating and higher probable upside, analysts clearly believe Globus Medical is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baxter International	3 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
Globus Medical	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.87

Globus Medical has a net margin of 18.92% compared to Baxter International's net margin of -9.70%. Baxter International's return on equity of 16.15% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baxter International	-9.70%	16.15%	5.24%
Globus Medical	18.92%	13.46%	11.65%

Baxter International has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Globus Medical has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Globus Medical has lower revenue, but higher earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baxter International	$11.24B	0.92	-$957M	-$2.13	N/A
Globus Medical	$2.94B	3.65	$537.87M	$4.30	18.40

90.2% of Baxter International shares are owned by institutional investors. Comparatively, 95.2% of Globus Medical shares are owned by institutional investors. 0.2% of Baxter International shares are owned by company insiders. Comparatively, 18.4% of Globus Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Globus Medical beats Baxter International on 15 of the 17 factors compared between the two stocks.

Get Globus Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMED vs. The Competition

Export

Metric	Globus Medical	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$10.24B	$7.04B	$6.66B	$23.14B
Dividend Yield	N/A	1.25%	2.68%	4.07%
P/E Ratio	18.40	47.59	24.50	31.62
Price / Sales	3.65	74.65	574.55	22.79
Price / Cash	12.00	24.92	44.20	24.08
Price / Book	2.34	7.16	10.69	4.68
Net Income	$537.87M	$159.20M	$3.57B	$1.08B
7 Day Performance	-1.63%	-0.85%	0.68%	-0.82%
1 Month Performance	-0.85%	4.31%	3.91%	3.11%
1 Year Performance	37.86%	5.36%	28.49%	24.65%

Globus Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMED Globus Medical	4.691 of 5 stars	$79.12 +4.9%	$105.00 +32.7%	+37.9%	$10.24B	$2.94B	18.40	6,000	Positive News High Trading Volume
BDX Becton, Dickinson and Company	4.9318 of 5 stars	$145.61 -0.4%	$182.73 +25.5%	-14.6%	$40.30B	$21.84B	36.86	72,000	Positive News
DXCM DexCom	4.5836 of 5 stars	$74.22 -1.5%	$84.83 +14.3%	-10.5%	$29.08B	$4.66B	31.72	11,000	Positive News Insider Trade
RMD ResMed	4.9367 of 5 stars	$193.05 -0.9%	$279.82 +44.9%	-24.7%	$28.25B	$5.15B	18.62	10,600	Analyst Forecast
STE STERIS	4.9112 of 5 stars	$205.80 -0.9%	$278.00 +35.1%	-14.2%	$20.23B	$5.94B	25.95	17,937	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GMED) was last updated on 6/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Globus Medical (GMED) Competitors

GMED vs. BDX, DXCM, RMD, STE, and BAX

How does Globus Medical compare to Becton, Dickinson and Company?

Summary

How does Globus Medical compare to DexCom?

Summary

How does Globus Medical compare to ResMed?

Summary

How does Globus Medical compare to STERIS?

Summary

How does Globus Medical compare to Baxter International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMED vs. The Competition

Globus Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Globus Medical (GMED) Competitors

GMED vs. BDX, DXCM, RMD, STE, and BAX

How does Globus Medical compare to Becton, Dickinson and Company?

Does the media favor BDX or GMED?

Which has stronger earnings & valuation, BDX or GMED?

Do analysts recommend BDX or GMED?

Which has more volatility and risk, BDX or GMED?

Is BDX or GMED more profitable?

Do insiders & institutionals hold more shares of BDX or GMED?

Summary

How does Globus Medical compare to DexCom?

Is GMED or DXCM more profitable?

Which has preferable valuation and earnings, GMED or DXCM?

Do analysts prefer GMED or DXCM?

Does the media refer more to GMED or DXCM?

Which has more volatility and risk, GMED or DXCM?

Do insiders and institutionals hold more shares of GMED or DXCM?

Summary

How does Globus Medical compare to ResMed?

Do analysts recommend GMED or RMD?

Do institutionals & insiders hold more shares of GMED or RMD?

Is GMED or RMD more profitable?

Does the media refer more to GMED or RMD?

Which has preferable valuation & earnings, GMED or RMD?

Which has more volatility and risk, GMED or RMD?

Summary

How does Globus Medical compare to STERIS?

Does the media refer more to GMED or STE?

Is GMED or STE more profitable?

Do analysts rate GMED or STE?

Which has more volatility and risk, GMED or STE?

Do institutionals and insiders have more ownership in GMED or STE?

Which has stronger valuation & earnings, GMED or STE?

Summary

How does Globus Medical compare to Baxter International?

Does the media prefer BAX or GMED?

Do analysts recommend BAX or GMED?

Is BAX or GMED more profitable?

Which has more volatility & risk, BAX or GMED?

Which has better earnings & valuation, BAX or GMED?

Do insiders & institutionals believe in BAX or GMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMED vs. The Competition

Globus Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools